Skip to content

Taysha Gene Therapies

US · TSHA #3015 by market cap Listed 2020
3.72 -0.05 -1.33%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Quant vs Street three independent views, side by side

StockVane factor grade
D+
Momentum strategy signal
Sell
Analyst consensus
Buy

Mostly aligned, one view stands apart.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

Analyst consensus 4 analysts

Buy
Avg price target 14.33 +285.2%
Price target rangecurrent 3.72
Low12.00
Avg14.33
High17.00
Buy 100% Hold 0% Sell 0%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-11-13 CCORF -- Buy 17.00
2026-11-13 BMO Capital -- Buy 14.00
2026-10-16 Piper Sandler -- Buy 12.00
2026-09-17 Wolfe Research -- Buy --
2026-08-14 BofA Securities -- Buy --
2026-08-12 Piper Sandler -- Buy 12.00
2026-08-12 Needham -- Buy 12.00
2026-08-11 Cantor Fitzgerald -- Buy 19.00
2026-08-11 CCORF -- Buy 17.00
2026-08-11 Goldman Sachs -- Buy 13.00
2026-07-20 Goldman Sachs -- Buy 13.00
2026-07-01 Needham -- Buy 12.00
2026-06-30 Piper Sandler -- Buy 12.00
2026-06-30 Baird -- Buy 15.00
2026-06-30 Needham -- Buy 12.00
2026-06-30 BMO Capital -- Buy 14.00
2026-06-23 Citizens JMP -- Buy 11.00
2026-06-23 BMO Capital -- Buy 14.00
2026-06-22 BofA Securities -- Buy 10.00
2026-06-22 Needham -- Buy 12.00
2026-05-07 Wells Fargo -- Buy 11.00
2026-05-06 CCORF -- Buy 17.00
2026-05-06 Needham -- Buy 12.00
2026-04-15 Needham -- Buy 12.00
2026-04-06 CCORF -- Buy 17.00

Price target trend monthly average, last 3 years

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2026/Q3 2026-11-12 -- ±20.05% -1.64% (in line)
2026/Q2 2026-08-11 -- ±16.55% +4.87% (in line)
2026/Q1 2026-05-06 -- ±16.94% +0.58% (in line)
2025/Q4 2026-03-19 -- ±18.21% +2.47% (in line)
2025/Q3 2025-11-04 -- ±25.78% -4.26% (in line)
2025/Q2 2025-08-12 -- ±27.36% +5.43% (in line)
2025/Q1 2025-05-15 -- ±39.49% +8.02% (in line)
2024/Q4 2025-02-26 -- ±50.80% -4.71% (in line)
2024/Q3 2024-11-13 After close ±30.32% +2.71% (in line)
2024/Q2 2024-08-12 -- ±33.49% -2.39% (in line)
2024/Q1 2024-05-14 After close ±28.44% +21.01% (in line)
2023/Q4 2024-03-19 After close ±45.16% +31.56% (in line)

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 20:02:39 · For reference only, not investment advice and not tailored to your situation.

Taysha Gene Therapies discussion 0 comments

Add a comment